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ABSTRACT
The triple antibiotic formulation, known as anti-MAP therapy, exhibits unique synergistic
antimicrobial activity and should be effective for treatment of Crohn’s disease (CD) associated
with Mycobacterium avium subspecies paratuberculosis (MAP). The absence of MAP detection
in some CD cases may be linked to poor diagnostics or lack of association with the disease. To
understand the therapeutic response of some CD patients to anti-MAP therapy in absence of
MAP detection, the immunomodulatory potency of anti-MAP therapy and its major ingredients,
clarithromycin (CLA) and rifabutin (RIF), in THP-1, Caco-2, and Jurkat T-cells were
investigated. Anti-MAP formulation at 2.0 µg/mL decreased MAP viability in macrophages by
18-fold over 72 h. Additionally, M1/M2 macrophage polarization ratio was reduced by 6.7-fold,
and expression and protein levels of TNF-α and IL-6 were reduced by 2.9-fold, whereas IL-10
increased by 5.0-fold in these cells. Mechanistically, the effect of anti-MAP formulation on NFκB activation was dose-dependent and decreased to 13.4% at 2.0 µg/mL. Anti-MAP therapy also
reversed the pro-inflammatory response in lipopolysaccharide (LPS)-induced macrophages,
which shows that the anti-inflammatory effect of the treatment is not just due to a decrease in
MAP viability. Furthermore, this study shows that anti-MAP therapy exhibits anti-cytotoxic
effects in Caco-2 monolayers infected with MAP or treated with dextran sodium sulfate (DSS).
Anti-MAP therapy decreased T-cell proliferation by up to 4.8-fold following treatment with
phytohemagglutinin (PHA) or MAP purified protein derivative (PPD). Overall, the data
demonstrate that anti-MAP therapy plays a significant role in modulating and eliciting a
protective immune response in macrophages, endothelial cells, and T lymphocytes, even in
absence of infection. This may explain the therapeutic response of some CD patients to
treatment, even in absence of MAP detection, infection, or total eradication. The study supports
anti-MAP therapy as an alternate treatment option for CD, especially in absence of reliable MAP
diagnostics.
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CHAPTER 1: INTRODUCTION
This chapter has been published in part and is reproduced here with permission from the
copyright holder. The article citation is: Qasem, A., Elkamel, E., and Naser, S.A. (2020). AntiMAP Triple Therapy Supports Immunomodulatory Therapeutic Response in Crohn’s Disease
through Downregulation of NF-κB Activation in the Absence of MAP Detection. Biomedicines,
8 (11): 513. doi: 10.3390/biomedicines8110513.
Crohn’s disease (CD) is a chronic inflammatory bowel disease that can affect different
areas of the gastrointestinal tract and currently has no medical or surgical cure [1]. CD is most
prevalent in North America and Europe where it affects about 3.2 per 1,000 people [2]. The
prevalence of CD has been increasing and is expected to cause a higher burden on the healthcare
system, which reflects the necessity for further research to establish better treatments for CD and
find a cure [3]. Numerous studies have linked Mycobacterium avium subspecies
paratuberculosis (MAP) to the etiology of CD, and environmental and genetic factors play a
major role in increasing susceptibility to MAP infection [4-6]. However, the current
recommended treatments guidelines for CD are targeted towards reducing inflammatory
symptoms and slowing the progression of the disease, but they do not target microbial triggers
such as MAP [4-7]. Many of the current recommended treatments are also associated with
significant adverse effects such as dependency on steroids, excessive immune suppression, and
hypersensitivity [8-9].
Current approaches to manage CD symptoms include treatment with aminosalicylates,
corticosteroids, immunosuppressants, and biologics [8]. Aminosalicylates can be used to treat
mild CD symptoms, but they are often associated with significant side effects and are now
considered to be of limited benefit [10,11]. Corticosteroids are useful for short-term symptom
alleviation and are commonly prescribed to treat mild to moderate CD due to their ease of use
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and effectiveness for some patients [12]. However, these advantages are countered by their
adverse side effects, toxicity, and loss of effectiveness over time, thus making them only a
temporary solution [12]. Immunosuppressants, such as azathioprine and 6-mercaptopurine, have
been used to treat active CD, although evidence supporting their use remains controversial [13].
Not only are they associated with side effects such as increased risk of infection, but there are
conflicting reports regarding their efficacy [14,15]. For example, a Cochrane review reported
that 48% of patients that received treatment with azathioprine or 6-mercaptopurine achieved
remission compared to only 37% of placebo patients; this difference in clinical improvement was
not statistically significant between the two groups [15]. Evidence supporting the use of these
treatments is limited [16]. CD patients that do not respond to these conventional therapies are
often treated with biologics such as anti-tumor necrosis factor alpha (anti-TNFα) inhibitors [17].
Anti-TNFα inhibitors, such as infliximab and adalimumab, have been shown to be effective at
inducing and maintaining remission for some CD patients [18,19] However, up to 40% of
patients are unresponsive to anti-TNFα therapy and secondary loss of response occurs in up to
10% of patients after one year [20-22]. Furthermore, after treatment withdrawal, there is a
relapse rate of 30-40% at 1 year [23]. Anti-TNFα therapy is also associated with several side
effects and adverse events such as development of skin lesions, susceptibility to infection,
immune reactions, and potential risk of malignancy [24-26]. There is also evidence that antiTNFα inhibitors worsen symptoms in CD patients with MAP infection because they promote
MAP survival, which may further exacerbate disease symptoms [27]. It is evident that there is
still an urgent need for improved treatment options to overcome the challenges that CD patients
face.
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Since CD may be associated with MAP infection, anti-MAP therapy may be a highly
promising treatment strategy for CD patients, especially because it has the potential to induce
remission without causing significant adverse events such as those associated with existing CD
treatments. Recently, our lab showed that the triple antibiotic drug formulation known as RHB104, which contains 63.3% clarithromycin (CLA), 30% rifabutin (RIF), and 6.7% clofazimine
(CLO), has synergistic bactericidal effects against MAP bacteria [28]. RHB-104 was tested
against clinical MAP strains isolated from CD patients, and the minimum inhibitory
concentration (MIC) ranged from 0.25 to 10 µg/mL [28]. These concentrations were lower than
the MIC of the individual antibiotic components, which ranged from 0.5 to 20 µg/mL [28].
Currently, RHB-104 is subjected to investigation in an FDA approved phase III clinical trial to
treat patients with moderate to severe CD [29].
Besides its antibacterial properties, RHB-104 is suspected to exhibit anti-inflammatory
effects as well, thus further supporting its use as a treatment option for CD patients. Several
antibiotics have demonstrated anti-inflammatory effects that are independent of their bactericidal
activity [30]. Specifically, clinical reports have shown that members of macrolide and rifamycin
antibiotic classes have been utilized as useful treatments to suppress inflammation in some
dermatological conditions that are unrelated to infectious factors [31]. CLA is a semisynthetic
macrolide that exhibits its antibacterial effects through inhibiting protein synthesis by reversibly
binding to the peptide exit tunnel of large (50S) ribosomal subunits, thus preventing peptide
chain elongation [32]. It was reported that CLA exhibits anti-inflammatory effects by inhibiting
activation of nuclear factor κB (NF-κB) and pro-inflammatory cytokine production such as of
TNF-α, IL-1α, IL-1β, and GM-CSF, as well as increasing the production of the antiinflammatory cytokine, IL-10, in vitro [33,34]. Additionally, CLA has shown some efficacy in
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alleviating active CD symptoms when patients were administered with an oral dosage form of
CLA [35].
Rifamycin antibiotics are effective at very low concentrations and exhibit their effects by
inhibiting the β-subunit of DNA-dependent RNA polymerases [36]. Studies have shown that RIF
can protect against the emergence of CLA resistance, which is why these two antibiotics are
commonly used together [37]. Rifamycins have been shown to have strong anti-inflammatory
properties through stimulation of pregnane X receptor (PXR) transcriptional activity and
inhibition of NF-κB activation [38]. These effects were observed for the rifamycin antibiotics,
rifamycin SV, rifampicin, and rifaximin [38], which are all structurally similar to RIF. As a
nuclear receptor, PXR induces expression of cytochrome P450 3A4 (CYP3A4) and Pglycoprotein P (PgP) in the gastrointestinal tract, thus leading to intracellular detoxification [38].
Both these genes were found to be significantly downregulated in CD patients, and the activation
of PXR by rifamycin antibiotics would help maintain intestinal barrier function and reduce
inflamed intestinal epithelia [38].
Although several studies strongly support the association between MAP infection and CD
pathogenesis, MAP was only detected in up to 70% of clinical samples from CD patients [4,6].
In contrast, other studies have reported lower incidence of MAP infection among CD patients in
comparison to healthy controls, which might be because different methodology was used for
MAP detection in human samples [39]. Detection of MAP in cultures of blood, breast milk, and
intestinal tissue was reported using RT-qPCR and nested PCR techniques [40]. At least one third
of CD patients may not have MAP infection or they may have it at levels below the limit of
detection provided by available techniques. Collectively, the lack of more reliable diagnostics or
the fact that MAP may not be associated with some CD cases may have contributed to the
4

conflicting reports about the role and significance of MAP in CD etiology. It is even more
puzzling that in case studies, some CD patients who were not tested for MAP responded well to
antibiotics-based treatments [35]. Regardless of MAP’s role in CD and other autoimmune
diseases, the bacterium should be eradicated. This can be effectively achieved using
antimicrobial-based therapy including antibiotics. To address these intriguing circumstances, this
study aims to examine treatment options that may offer dual benefits by eradicating MAP
infection if it is present, and at the same time reducing inflammation through an
immunomodulatory mechanism. Ingredients of RHB-104 triple therapy have been reported to
induce a positive therapeutic response in CD patients [41]. Understanding the effect of these
antibiotics in stimulated macrophages by infection or antigens would help to elucidate the
therapeutic response in CD cases. There is no doubt that current treatment options have several
significant limitations and may not provide a long-term therapeutic response for patients [10-13,
20-26].
A common characteristic of CD patients is overexpressed levels of several proinflammatory cytokines and chemokines, as well as significantly higher NF-κB activity
compared to healthy individuals [42, 43]. The T lymphocytes of CD patients are also
characterized by rapid cycling, and restoration of apoptosis by RHB-104 may contribute to
reducing inflammation and have positive therapeutic effects [44]. Studies have shown that CD
patients exhibit higher levels of enterocyte apoptosis in inflamed areas of the intestine [45], and
antibiotic treatment may prevent or reduce oxidative stress in these cells. Therefore, the
combined bactericidal and anti-inflammatory properties of CLA and RIF as part of the RHB-104
drug formulation should enhance the efficacy of these antibiotics for CD treatment. Aside from
the synergistic bactericidal activity of RHB-104, the present study aims to investigate the
5

synergistic anti-inflammatory and immunomodulatory effects of anti-MAP therapy represented
by RHB-104, compared to its individual components, both in the presence and absence of MAP
infection in THP-1 macrophages, Caco-2 monolayers, and Jurkat T-cells.
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CHAPTER 2: MATERIALS AND METHODS
This chapter has been published in part and is reproduced here with permission from the
copyright holder. The article citation is: Qasem, A., Elkamel, E., and Naser, S.A. (2020). AntiMAP Triple Therapy Supports Immunomodulatory Therapeutic Response in Crohn’s Disease
through Downregulation of NF-κB Activation in the Absence of MAP Detection. Biomedicines,
8 (11): 513. doi: 10.3390/biomedicines8110513.
Infection and Treatment of Monocyte-Derived Macrophages
The THP-1 cell line (ATCC TIB-202) was cultured in RPMI-1640 medium (ATCC 302001) with 10% fetal bovine serum (FBS; Sigma Life Science, St. Louis, MO, USA). The cells
were maintained in a humidified 5% CO2 incubator at 37°C and grown to confluency in cell
culture flasks. A total of 1.0 mL of cell suspension was transferred to 12-well tissue culture
plates with 1×105 cells per well. They were then differentiated into monocyte-derived
macrophages using 50 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma Life Science, St.
Louis, MO, USA) followed by 24 h of incubation at 37°C. Next, monocyte-derived macrophages
were treated with 5 µg/mL lipopolysaccharide (LPS) or infected with clinical MAP UCF4 (1×107
CFU/mL), followed by 24 h of incubation at the same conditions. Representative of anti-MAP
therapy (RHB-104), CLA, and RIF, were kindly provided by RedHill Biopharma Inc. RHB-104
capsule formulation was dissolved in a single proprietary solvent to a final concentration of 1
mg/mL. The stock solution of CLA (1 mg/mL) was prepared by dissolving its powder form in
0.5 M sodium acetate, and the stock solution of RIF (1 mg/mL) was prepared by dissolving its
powder form in absolute methanol. Cells were then treated in triplicate with different
concentrations of RHB-104 (0.5, 1.0, 2.0 μg/mL) in addition to the corresponding component
concentrations of CLA (0.32, 0.63, 1.26 μg/mL), and RIF (0.15, 0.30, 0.60 μg/mL). Cells were
incubated for an additional 24 h at the same conditions, and then subjected to further testing. For
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analysis of iNOS and CD206 expression levels, cells were treated with LPS or infected with
MAP and simultaneously treated with antibiotics.

Measurement of MAP Viability in Infected Macrophages
After 24 h of infection with MAP, monocyte-derived macrophages were washed twice
with PBS to remove extracellular bacteria, and then antibiotics were added, and the cells were
incubated for an additional 24 h. Monocyte-derived macrophages were collected at three time
points: 24, 48, and 72 h. The cells were lysed, and then the samples were centrifuged at 14,000
rpm for 20 min. Supernatants were collected and the LIVE/DEAD™ BacLight™ Bacterial
Viability Kit (Thermo Fisher Scientific, Waltham, MA, USA) was used according to the
manufacturer’s protocol as described earlier [40]. Briefly, 100 µL of each bacterial suspension
was pipetted into separate wells of a 96-well flat-bottom microplate in triplicate and mixed with
100 µL of stain solution. The plate was then incubated for 15 min at room temperature (RT) in
the dark. Fluorescence was measured using a microplate reader at 530 nm to determine the
proportion of live bacteria (green), and at 630 nm to determine the proportion of dead bacteria
(red). Data were analyzed by generating a standard plot using fluorescence measurements of five
different proportions of live to dead MAP including 0:100, 10:90, 50:50, 90:10, and 100:0. These
samples were pipetted in triplicate at volumes of 100 µL and mixed with 100 µL of stain
solution. A graph was generated, and the equation of the least squares fit of the relationship
between percent live bacteria (x) and green/red fluorescence ratio (y) was used to calculate
bacterial viability of the MAP-infected cells treated with antibiotics.
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Measurement of NF-κB Transcription Factor Activation in Macrophages
Nuclei were extracted from 1.0 mL of each monocyte-derived macrophage sample
suspension after 24 h of antibiotic treatment, using the nuclear extraction kit by Abcam
(Cambridge, UK) according to the manufacturer’s protocol. Briefly, cells were centrifuged at
1000 rpm for 5 min and then pellets were suspended in 100 μL of 1X pre-extraction buffer.
Following 10 min of incubation on ice, the samples were vortexed for 10 sec and then
centrifuged at 12,000 rpm for 1 min. The nuclear pellets were then mixed with 20 μL of
extraction buffer containing protease inhibitor cocktail (PIC) and dithiothreitol (DTT) at a
1:1000 ratio. Samples were then incubated on ice for 15 min with periodic vortexing (5 s) every
3 min. Finally, suspensions were centrifuged at 14,000 rpm for 10 min at 4°C and the
supernatants containing nuclear fractions were saved at −80°C until further use. Protein
concentrations were quantified using NanoDrop (OD at 280 nm). The NF-κB p65 Transcription
Factor Assay Kit by Abcam (Cambridge, UK) was used to determine NF-κB activation,
according to the manufacturer’s protocol. Briefly, nuclear extracts were added to wells, which
were coated with a dsDNA sequence specific to NF-κB p65, and the plate was incubated
overnight at 4°C. A transcription factor NF-κB p65 positive control provided by the kit was
included as well as a negative control, which omitted NF-κB p65. The plate was then washed 5
times using 1X wash buffer to remove unbound reagents. NF-κB p65 primary antibody was
added to each well and the plate was incubated for 1 h on an orbital shaker at RT. Following five
washes, diluted transcription factor goat anti-rabbit HRP conjugate secondary antibody was
added and incubated for an additional 1 h on an orbital shaker at RT. Following five washes,
developing reagents were added to the wells and absorbance was read at 450 nm. Percent
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activation scores were calculated by the equation: (sample absorbance reading/positive control
absorbance reading) × 100.

Measurement of iNOS, CD206, TNF-α, IL-6, and IL-10 Expression in Treated Macrophages
RNA was isolated from each 1.0 mL sample of monocyte-derived macrophages
following 24 h of antibiotic treatment. RNA was then reverse-transcribed to cDNA, then gene
expression was measured using specific primers for GAPDH, iNOS, CD206, TNF-α, IL-6, and
IL-10 obtained from Invitrogen (Carlsbad, CA, USA) (Table 1), followed by quantitative reverse
transcription PCR (RT-qPCR) analysis. To isolate RNA, cells were centrifuged at 2,500 rpm for
5 min at 4°C and then pellets were suspended in 500 µL of TRIzol reagent (Invitrogen, Carlsbad,
CA, USA) and left at RT for 5 min. Next, 125 µL of chloroform was added to each sample
followed by an additional 5 min incubation period at RT. The samples were then centrifuged at
10,000 rpm for 5 min at 4°C and the top clear aqueous layers containing RNA were transferred
to new 2.0 mL microcentrifuge tubes. These were then gently mixed with 275 µL of 100%
isopropanol, incubated at RT for 5 min, and then centrifuged at 14,000 rpm for 20 min at 4 °C.
Next, the samples were placed on ice and the isopropanol was poured off, and 500 µL of 75%
ethanol in DEPC-treated water was added. The samples were centrifuged at 9,500 rpm for 5 min
at 4°C. Ethanol was then poured off and the pellets were left to air-dry for 10 min. Finally, 15 µL
of DEPC-treated water was added to each tube and gently mixed. RNA concentrations were
measured using NanoDrop (OD at 260 nm). Next, cDNA was synthesized from 800 ng of each
RNA sample, 4 µL of iScript reverse transcription supermix (Bio-Rad, Hercules, CA, USA), and
then topped up to a total volume of 20 µL with RNase-free water. A thermal cycler (MyGene
Series Peltier Thermal Cycler) was used to perform the reactions for 5 min at 25°C, 20 min at
10

46°C, and 1 min at 95°C. The cDNA samples were either stored at −20°C or used immediately
for RT-qPCR analysis. For each sample, 1 µL of cDNA was mixed with 10 µL of Fast SYBR
Green Master Mix (Thermo Fisher Scientific, Waltham, MA), 1 µL of forward primer, 1 µL of
reverse primer (see Table 1), and 7 µL of DEPC-treated water. Samples were added in triplicate
to a 96-well microamp RT-PCR reaction plate and the experiment was run using 7500 Fast RealTime PCR System (Applied Biosystems, Foster City, CA, USA). GAPDH was used as a control
to get baseline CT values, and gene expression of iNOS, CD206, TNF-α, IL-6, and IL-10 were
measured. Relative gene expression levels were calculated using: (2−∆CT ) × 1000, where ∆CT =
CTsample − CTGAPDH .

Measurement of TNF-α, IL-6, and Il-10 Protein Expression in Treated Macrophages
Following 24 h of antibiotic treatment, monocyte-derived macrophages were pelleted by
centrifugation at 2,500 rpm for 5 min at 4°C. The supernatants were saved and TNF-α, IL-6, and
Il-10 protein levels were determined using the following ELISA kits: Human TNF-α High
Sensitivity ELISA, Human IL-6 High Sensitivity ELISA, and Human IL-10 High Sensitivity
ELISA, all of which were purchased from Invitrogen (Carlsbad, CA, USA). All groups were
tested in triplicate.

Caco-2 Cell Culture and Treatment
The antioxidant effects of antibiotics were evaluated in a human enterocyte-like cell line
(Caco-2 ATCC HTB-37). Cells were routinely cultured in ATCC-formulated Eagle’s Minimum
Essential Medium (EMEM) supplemented with 20% FBS (ATCC, Manassas, VA, USA) and
maintained at 37°C in a humidified 5% CO2 incubator. Cells were grown in 12-well plates at a
11

density of 3×105 cells per well until confluency and differentiation were reached in 21 days.
Fully differentiated Caco-2 monolayers in 12-well plates were infected with 1×107 CFU/mL of
MAP UCF4 or 3% dextran sodium sulfate (DSS) for 24 h in the presence of either RHB-104 (1.0
μg/mL), CLA (0.63 μg/mL), or RIF (0.30 μg/mL). Caco-2 monolayers were then lysed, and
lactate dehydrogenase (LDH) and glutathione (GSH) levels were measured.

Trypan Blue Exclusion Assay in Caco-2 Monolayers
RHB-104 and its major components were evaluated for their ability to prevent cytotoxic
effects caused by MAP in Caco-2 monolayers using a trypan blue exclusion assay (Thermo
Fisher, Waltham, MA, USA). Following 24 h of infection and antibiotic treatment, supernatant
was removed, and monolayers were washed with fresh media. Next, 10 μL of trypan blue
solution was added to each sample and monolayers were incubated at RT for 30 min. Finally,
trypan blue was removed, monolayers were examined under the microscope, and pictures were
taken at 100× magnification.

Measuring LDH Activity in Caco-2 Monolayers
The CyQUANT LDH cytotoxicity assay (Invitrogen, Carlsbad, CA, USA) was used to
quantify cellular LDH cytotoxicity levels using a fluorescent-based method. Briefly, following
the manufacturer instructions, two sets of triplicate wells in a 12-well plate were prepared.
Following MAP infection or DSS treatment in the presence of antibiotics for 24 h, one set of
each treated monolayers was lysed and used to determine maximum LDH activity, and the
second set was used to determine spontaneous LDH activity. A total of 50 μL of each sample
medium and positive control was transferred into a 96-well plate in triplicate and then mixed
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with 50 μL of reaction mixture. After a 10 min incubation at RT, 50 μL of stop solution was
added and fluorescence was measured using an excitation of 560 nm and an emission of 590 nm.
Cytotoxicity was calculated using the formula: (treated sample LDH − spontaneous
LDH)/(maximum LDH − spontaneous LDH) × 100. Each value was divided by the positive
control value to determine the percent decrease in LDH activity.

Measuring Reduced GSH Levels in Caco-2 Monolayers
To determine GSH levels following MAP infection or DSS treatment in the presence of
antibiotics, the reduced GSH assay kit (Sigma Life Science, St. Louis, MO, USA) was used
according to the manufacturer’s instructions. Briefly, 100 μL of collected cell pellets were mixed
with 100 μL of 5% sulfosalicylic acid solution and vortexed vigorously. Samples were then
centrifuged at 12,000×g at 4°C for 20 min. Supernatants were collected, followed by a 5-fold
dilution in GSH assay buffer, and then 10 μL were transferred into a 96-well plate in triplicate.
Six serial dilutions were prepared from the GSH positive control provided by the kit and added
to the plate to generate a standard curve. Finally, 80 μL of reaction mix were added to each well
and absorbance was measured at 450 nm. The amount of GSH in nmol/mg was calculated from
the generated curve equation.

DHE Fluorescence Staining Assay
Dihydroethidium (DHE) fluorescence staining was performed on Caco-2 monolayers
following MAP infection and antibiotics treatment for 24 h. Monolayers were washed twice with
cold PBS, and then fixed with 4% paraformaldehyde (PFA) for 15 min. Monolayers were then
washed twice with cold PBS, and then treated with 1 μM DHE stain (Sigma Aldrich, St. Louis,
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MO, USA) for 25 min. Next, 60 μL VECTASHIELD Antifade Mounting Medium containing
4′,6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA, USA) was used to
co-stain nuclei. Slides were examined under AmScope IN480TC-FL-MF603 Fluorescence
Microscope, where red staining indicates oxidative stress and blue staining represents nuclei.
Captured images were analyzed by measuring average integrated density using NIH Image J
1.39o software (Rockville, MD, USA), which was also used to generate merged images.

T-Cell Proliferation Assay Following Antibiotic Treatment
The Jurkat T-cell line (ATCC TIB-152) was used and cultured in RPMI-1640 medium
(ATCC 30-2001) with 10% FBS (Sigma Life Science, St. Louis, MO, USA). The cells were
maintained in a humidified 5% CO2 incubator at 37°C and grown to confluency in cell culture
flasks. Moreover, 2×105/mL of isolated T-cells were transferred to a 96-well culture plate with
100 μL aliquots per well and then incubated either with RPMI only, 10 μg/mL
phytohemagglutinin (PHA; Sigma Life Science, St. Louis, MO, USA), or 5 μg/mL MAP puriﬁed
protein derivative (PPD), and concurrently treated in triplicate with 1.0 μg/mL RHB-104, 0.63
μg/mL CLA, or 0.30 μg/mL RIF. MAP PPD was prepared from sonicates of protein extracts
from cell pellets of MAP UCF4, followed by centrifugation at 16,000 rpm for 30 min, and then
isolation of the supernatant containing PPD. The cells were incubated for 48 h in a humidified
5% CO2 incubator at 37°C. A T-cell proliferation assay was performed using the
bromodeoxyuridine (BrdU) labeling proliferation ELISA kit by Abcam (Cambridge, UK) as per
the manufacturer’s protocol. Briefly, T-cells were labelled using 20 μL of 1X BrdU and
incubated for an additional 24 h at 37°C under the same conditions. Then, 200 μL of fixing
solution was added to each well and then incubated for 30 min at RT. The plate was then washed
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3 times using 1X wash buffer. Next, 100 μL of anti-BrdU monoclonal detector antibody was
added to each well and the plate was incubated for 1 h at RT. The wells were washed and then
100 μL of 1X peroxidase goat anti-mouse IgG conjugate was added to each well, and the plate
was incubated at RT for 30 min. Following another wash step, a total of 100 μL of TMB
peroxidase substrate was added to each well and the plate was incubated in the dark for 30 min at
RT. Lastly, 100 μL of stop solution was added to the wells and absorbance was read at 450 nm
using a spectrophotometric microtiter plate. Relative T-cell proliferation of samples compared to
controls (T-cells with RPMI only) were determined by calculating fold change in absorbance
readings at 450 nm.

Statistical Analysis
GraphPad Prism V.7.02 (GraphPad, La Jolla, CA, USA) was used to analyze data
statistics. All data collected in this study were pre-tested for normal distribution using the
Kolmogorov–Smirnov normality test. The unpaired two-tailed t-test was used to determine
significance. Data are expressed as average ± SD of the mean, and the difference between treated
samples vs. controls was considered statistically significant at a level of p value < 0.05 and at
95% confidence interval (CI).
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CHAPTER 3: RESULTS
This chapter has been published in part and is reproduced here with permission from the
copyright holder. The article citation is: Qasem, A., Elkamel, E., and Naser, S.A. (2020). AntiMAP Triple Therapy Supports Immunomodulatory Therapeutic Response in Crohn’s Disease
through Downregulation of NF-κB Activation in the Absence of MAP Detection. Biomedicines,
8 (11): 513. doi: 10.3390/biomedicines8110513.
RHB-104 Decreases MAP Survival in Infected Macrophages at Lower Concentrations than CLA
and RIF
The effects of RHB-104 (0.5, 1.0, and 2.0 μg/mL) and its individual components, CLA
(0.32, 0.63, and 1.26 μg/mL), and RIF (0.15, 0.30, and 0.60 μg/mL) were tested on modulating
MAP viability in infected macrophages at three time points over 72 h. The results indicate that
RHB-104 at 0.5, 1.0, and 2.0 μg/mL reduced MAP viability significantly in a concentrationdependent manner over time (Figure 1A). At 2.0 μg/mL RHB-104, MAP viability declined from
100% to 29.97%, 15.37%, and 5.51% after 24, 48, and 72 h of treatment, respectively. The effect
of CLA on MAP viability was only significant at 1.26 μg/mL, where MAP viability declined
from 100% to 38.49%, 21.26%, and 17.58%, following 24, 48, and 72 h of treatment,
respectively (Figure 1B). However, RIF did not affect MAP viability significantly at all three
concentrations tested (Figure 1C).

RHB-104 Significantly Reduces M1/M2 Macrophage Polarization at Lower Concentrations than
its Major Components
The effects of RHB-104 (0.5, 1.0, and 2.0 μg/mL), CLA (0.32, 0.63, and 1.26 μg/mL),
and RIF (0.15, 0.30, and 0.60 μg/mL) were examined on the expression of the pro-inflammatory
M1 macrophage marker, iNOS, and the anti-inflammatory M2 macrophage marker, CD206,
following MAP infection or LPS treatment for 24 h. MAP-infected macrophages with no
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antibiotic treatment exhibited the highest levels of iNOS (5.97 ± 0.17) and the lowest levels of
CD206 (5.33 ± 0.51); these groups were used as reference controls. RHB-104 caused significant
reductions in iNOS expression at all concentrations tested in MAP-infected macrophages (4.13 ±
0.07, 3.49 ± 0.41, and 2.47 ± 0.95 at 0.5, 1.0, and 2.0 μg/mL, respectively) (Figure 2A).
However, CLA only caused significant reductions in iNOS expression at 0.63 and 1.26 μg/mL,
but not at 0.32 μg/mL (4.18 ± 0.51 and 3.35 ± 0.14 at 0.63 and 1.26 μg/mL, respectively) (Figure
2A). RIF did not cause significant reduction in iNOS at any of the concentrations tested in MAPinfected macrophages (Figure 2A). Additionally, RHB-104 caused significant upregulation of
CD206 expression in MAP-infected macrophages at all concentrations tested (10.90 ± 2.11,
12.85 ± 1.07, and 14.8 ± 0.92 at 0.5, 1.0, and 2.0 μg/mL, respectively) (Figure 2B). However,
CLA only caused significant upregulation of CD206 at a concentration of 1.26 μg/mL (10.95 ±
1.96) and RIF did not significantly affect CD206 expression (Figure 2B). These results are also
reflected in the iNOS/CD206 (M1/M2) ratios, which were significantly reduced in response to
RHB-104 at all concentrations tested (3.79 ± 0.44, 2.71 ± 0.40, and 1.68 ± 0.50 at 0.5, 1.0, and
2.0 μg/mL, respectively) compared to MAP-infected macrophages with no antibiotic treatment
(11.20 ± 0.34). CLA only exhibited significant reduction in M1/M2 following treatment with
0.63 and 1.26 μg/mL (5.86 ± 0.41 and 3.06 ± 0.34, respectively) (Figure 2C). Similar trends were
exhibited in response to antibiotic treatment in LPS-treated macrophages. Macrophages treated
with LPS and with no antibiotic treatment exhibited the highest levels of iNOS (6.45 ± 0.12) and
the lowest levels of CD206 (5.04 ± 0.56); these groups were used as reference controls. RHB104 caused significant downregulation of iNOS expression at all concentrations tested (4.43 ±
0.43, 3.74 ± 0.48, and 2.74 ± 0.14 at 0.5, 1.0, and 2.0 μg/mL, respectively) and significant
upregulation in CD206 at all concentrations tested (11.02 ± 0.13, 13.24 ± 0.57, and 15.08 ± 0.97
17

at 0.5, 1.0, and 2.0 μg/mL, respectively) in LPS-treated macrophages (Figure 3A,B). CLA only
caused significant downregulation of iNOS expression at 0.63 and 1.26 μg/mL (4.49 ± 0.64 and
3.83 ± 0.25, respectively), and significant upregulation of CD206 only at 1.26 μg/mL (10.36 ±
1.96) in LPS-treated macrophages (Figure 3A,B). RIF did not significantly change iNOS or
CD206 expression at any of the concentrations tested (Figure 3A,B). Additionally, M1/M2 ratios
were significantly reduced in response to RHB-104 treatment at all concentrations tested (4.02 ±
0.53, 2.83 ± 0.51, and 1.82 ± 0.97 at 0.5, 1.0, and 2.0 μg/mL, respectively) compared to LPStreated macrophages with no antibiotics (12.80 ± 0.62), followed by CLA only at the upper two
concentrations tested (6.60 ± 0.64 and 3.70 ± 0.41 at 0.63 and 1.26 μg/mL, respectively (Figure
3C).

RHB-104 Decreases NF-κB Activation in Macrophages More Effectively than its Major
Components
NF-κB activation was determined in MAP-infected and LPS-treated macrophages treated
with RHB-104, CLA, and RIF (Table 2). Activation scores represent the proportion of activated
NF-κB, as indicated by nuclear translocation of the NF-κB p65 subunit, in comparison to the
positive control. The results showed that RHB-104 exhibited reduced NF-κB activation in a
concentration-dependent manner at 0.5, 1.0, and 2.0 μg/mL in MAP-infected macrophages
(48.4%, 21.5%, and 13.4%, respectively) and LPS-treated macrophages (67.2%, 37.8%, and
23.3%, respectively). Clarithromycin also reduced NF-κB activation at 0.32, 0.63, and 1.26
μg/mL in MAP-infected macrophages (58.3%, 49.6%, and 24.1%, respectively) and LPS-treated
macrophages (68.2%, 57.2%, and 33.6%, respectively). However, the activation scores in
response to CLA treatment exhibited lower levels of reduction than RHB-104 treatment at
comparable concentrations. Rifabutin caused reduced NF-κB activation in a concentration18

dependent manner as well; however, the effects were not as strong as those seen by RHB-104
and CLA treatment. At 0.15, 0.30, and 0.60 μg/mL, RIF caused activation scores of 83.8%,
73.1%, and 57.5%, respectively, in MAP-infected macrophages, and 89.1%, 83.4%, and 68.7%,
respectively, in LPS-treated macrophages.

RHB-104 is Superior to Clarithromycin and Rifabutin at Modulating Cytokine Gene Expression
Relative gene expression of pro-inflammatory cytokines, TNF-α and IL-6, and the antiinflammatory cytokine, IL-10, were measured using RT-qPCR in response to RHB-104 (0.5, 1.0,
and 2.0 μg/mL), CLA (0.32, 0.63, and 1.26 μg/mL), and RIF (0.15, 0.30, and 0.60 μg/mL)
antibiotic treatment in MAP-infected and LPS-treated macrophages. Expression of TNFα and IL6 were highest (5.20 ± 0.25 and 5.30 ± 0.27, respectively), and IL-10 expression was lowest
(0.71 ± 0.27) in MAP-infected macrophages with no antibiotic treatment; these groups were used
as reference controls (Figure 4). Pro-inflammatory cytokine gene expression was significantly
reduced in response to RHB-104 treatment at concentrations of 1.0 and 2.0 μg/mL in MAPinfected macrophages. Specifically, TNF-α gene expression levels were 2.21 ± 0.07 and 1.79 ±
0.07 at 1.0 and 2.0 μg/mL, respectively, and IL-6 expression levels were 2.47 ± 0.28 and 1.81 ±
0.07 at 1.0 and 2.0 μg/mL, respectively (Figure 4A,B). However, CLA only exhibited significant
reduction in TNF-α and IL-6 expression at a concentration of 1.26 μg/mL (3.47 ± 0.16 and 3.78 ±
0.13, respectively) (Figure 4A,B). In contrast, RIF did not exhibit significant changes in gene
expression in TNF-α or IL-6 (Figure 4A,B). Furthermore, expression of the anti-inflammatory
cytokine, IL-10, was significantly increased in response to RHB-104 at all concentrations tested
(2.71 ± 0.13, 3.17 ± 0.20, and 3.52 ± 0.22 at 0.5, 1.0, and 2.0 μg/mL, respectively) (Figure 4C).
Both CLA and RIF did not exhibit significant changes in IL-10 expression at any of the tested
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concentrations (Figure 4C). In parallel to these results, similar findings were observed in LPStreated macrophages in response to the same antibiotic treatments. Expression of TNF-α and IL-6
were highest (6.70 ± 0.42 and 6.55 ± 0.36, respectively), and IL-10 expression was lowest (0.74
± 0.27) in LPS-treated macrophages with no antibiotic treatment; these groups were used as
reference controls (Figure 5). As shown in Figure 5A, RHB-104 caused significant reduction in
TNF-α expression at all concentrations tested (3.96 ± 0.13, 3.12 ± 0.17, and 2.52 ± 0.12 at 0.5,
1.0, and 2.0 μg/mL, respectively). RHB-104 also significantly reduced IL-6 expression at all
concentrations (4.28 ± 0.189, 3.40 ± 0.17, and 2.75 ± 0.06 at 0.5, 1.0, and 2.0 μg/mL,
respectively) (Figure 5B). However, CLA only significantly reduced expression of TNF-α and
IL-6 at 1.26 μg/mL (4.15 ± 0.27 and 4.35 ± 0.21, respectively) in LPS-treated macrophages
(Figure 5A,B). RIF did not cause significant changes in TNF-α or IL-6 expression. IL-10
expression levels were only significantly reduced by RHB-104 (2.07 ± 0.20, 2.36 ± 0.02, 2.76 ±
0.14 at 0.5, 1.0, and 2.0 μg/mL, respectively), but no significant changes were observed in
response to CLA or RIF antibiotic treatments in LPS-treated macrophages (Figure 5C).

RHB-104 is Superior to Clarithromycin and Rifabutin at Modulating Cytokine Protein Levels
To evaluate cytokine levels in MAP-infected and LPS-treated macrophages in response
to treatment with RHB-104 (0.5, 1.0, and 2.0 μg/mL), CLA (0.32, 0.63, and 1.26 μg/mL), and
RIF (0.15, 0.30 and 0.60 μg/mL), an ELISA-based approach was used (Table 3). TNF-α and IL-6
levels in MAP-infected macrophages with no antibiotic treatment were 191.2 ± 8.6 pg/mL and
201.8 ± 11.7 pg/mL, respectively, and IL-10 levels were 61.9 ± 9.8 pg/mL. Relative to these
MAP controls, RHB-104 showed significant downregulation of TNF-α at 1.0 and 2.0 µg/mL
with 123.7 ± 6.7 pg/mL and 95.8 ± 1.8 pg/mL, respectively. However, CLA only showed a
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significant decrease in TNF-α at 1.26 µg/mL (146.1 ± 6.2 pg/mL), and RIF showed no
significant change in TNF-α. Similarly, IL-6 levels were significantly reduced in response to 1.0
and 2.0 µg/mL RHB-104 (139.4 ± 3.2 pg/mL and 117.5 ± 2.5 pg/mL, respectively). CLA only
significantly reduced IL-6 at 1.26 µg/mL (153.2 ± 4.6 pg/mL), and RIF did not cause significant
changes in IL-6 in MAP-infected macrophages. The anti-inflammatory cytokine, IL-10, was
significantly increased in response to 1.0 and 2.0 µg/mL RHB-104 (88.6 ± 3.5 pg/mL and 95.1 ±
5.8 pg/mL, respectively), but both CLA and RIF did not significantly change IL-10 levels at any
of the concentrations tested. Comparably, similar trends were observed in LPS-treated
macrophages. LPS controls with no antibiotic treatment exhibited TNF-α and IL-6 levels of
217.4 ± 5.1 pg/mL and 224.3 ± 9.6 pg/mL, respectively, and IL-10 levels of 52.2 ± 7.4 pg/mL.
These control groups were used as reference standards for the groups with antibiotic treatment.
RHB-104 caused a relatively significant decrease in TNF-α at 1.0 and 2.0 µg/mL (139.7 ± 4.7
pg/mL and 110.9 ± 4.0 pg/mL, respectively) and in IL-6 at 1.0 and 2.0 µg/mL (151.1 ± 2.5
pg/mL and 137.2 ± 2.7 pg/mL, respectively). However, CLA only caused significant reductions
in TNF-α and IL-6 at 1.26 µg/mL (158.2 ± 7.3 pg/mL and 169.7 ± 1.1 pg/mL, respectively). RIF
did not significantly change TNF-α or IL-6 levels at any of the concentrations tested. Lastly, IL10 was significantly increased in response to 1.0 and 2.0 µg/mL RHB-104 (84.3 ± 6.9 pg/mL and
91.91 ± 5.2 pg/mL, respectively), but IL-10 did not significantly change in response to CLA or
RIF treatment at any of the tested concentrations.

RHB-104 Synergistically Reduces Tissue Damage and Oxidative Stress in Caco-2 Monolayers
The viability of MAP-infected or DSS-treated Caco-2 monolayers was detected with a trypan
blue exclusion assay, as shown in Figures 6 and 7 where areas of dark blue staining, as indicated
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by red arrows, represent dead cells. The test demonstrated a clear reduction in cell death upon
exposure of monolayers to RHB-104 (1.0 μg/mL), followed by CLA (0.63 μg/mL), and then RIF
(0.30 μg/mL), which only had a minimal effect on preventing cell death (Figures 6A–D and 7A–
D). To further confirm the findings, the effect of RHB-104 (0.5, 1.0, and 2.0 μg/mL) and its
individual components, CLA (0.32, 0.63, and 1.26 μg/mL) and RIF (0.15, 0.30 and 0.60 μg/mL),
were assessed on tissue damage and oxidative stress activity markers, LDH and GSH, in Caco-2
monolayers following 24 h of MAP infection or 3% DSS treatment. The groups infected with
MAP or treated with DSS without any antibiotics showed the highest levels of LDH and the
lowest levels of GSH and were used as reference controls. RHB-104 significantly decreased
LDH levels at 1.0 and 2.0 μg/mL (50.32 ± 3.9% and 41.68 ± 2.4%, respectively) in MAPinfected monolayers (Figure 6E). In addition, Figure 7E showed that RHB-104 at 1.0 and 2.0
μg/mL had similar effects on LDH levels in DSS-treated monolayers (60.23 ± 2.6% and 47.61 ±
4.2%, respectively), whereas CLA only significantly decreased LDH activity levels at 1.26
μg/mL (52.47 ± 5.3% and 60.41 ± 3.1, respectively) in both MAP-infected and DSS-treated
monolayers (Figures 6E and 7E). Similarly, the antioxidant effect of RHB-104 was significantly
higher than its individual components by increasing GSH levels at 1.0 and 2.0 μg/mL (75.41 ±
3.3% and 87.27 ± 2.3%, respectively) in MAP-infected monolayers, and similar effects were
found at 1.0 and 2.0 μg/mL (61.09 ± 4.2% and 80.23 ± 6.3%, respectively) in DSS-treated
monolayers (Figures 6F and 7F). The effect of CLA on GSH activity was only significant at 1.26
μg/mL in both MAP-infected and DSS-treated monolayers (70.19 ± 6.7% and 65.43 ± 2.4,
respectively) (Figures 6F and 7F). In contrast, RIF did not show any significant effects on LDH
or GSH activity in either MAP-infected or DSS-treated monolayers at all three tested
concentrations (Figures 6E,F and 7E,F). Oxidative stress levels in MAP-infected fully
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differentiated Caco-2 monolayers were also measured by DHE fluorescence staining assay
(Figure 8). MAP infection caused the highest level of oxidative stress, whereas RHB-104 (1.0
μg/mL) and CLA (0.63 μg/mL) caused significant reductions in oxidative stress levels compared
to the MAP control. Additionally, RHB-104 caused a significantly greater reduction in oxidative
stress levels compared to RIF (0.30 μg/mL) and a slight decrease in oxidative stress levels
compared to CLA (0.63 μg/mL), while CLA did not cause a significant reduction in oxidative
stress levels compared to RIF (0.30 μg/mL). Figure 9 shows the oxidative stress levels in fully
differentiated Caco-2 monolayers infected with different concentrations of MAP: 0.25×105
CFU/mL, 0.5×105 CFU/mL, and 1.0×105 CFU/mL. All three MAP concentrations significantly
increased reactive oxygen species (ROS) compared to the control (no treatment), as measured by
quantification of DHE fluorescence, but the difference between varying MAP concentrations was
not significant. Furthermore, Caco-2 monolayers infected with 0.25×105 CFU/mL MAP and
treated with 1.0 μg/mL showed a significant reduction in ROS compared to cells with just MAP
infection. Figure 10 represents Caco-2 monolayers treated only with RHB-104 at concentrations
of 0.5 μg/mL, 1.0 μg/mL, and 2.0 μg/mL to assess whether these treatments are harmful to cells.
The results show that RHB-104 did not increase oxidative stress levels at any concentration. In
fact, RHB-104 reduced ROS with increasing concentrations. This reduction was significant at
concentrations of 1.0 μg/mL and 2.0 μg/mL relative to the control (no treatment).

RHB-104 Most Effectively Reduces T-cell Proliferation in Phytohemagglutinin (PHA) and MAP
PPD-Treated Cells
T-cell proliferation was measured in PHA- and MAP PPD-treated T-cells in the presence
and absence of treatment with 1.0 μg/mL RHB-104, 0.63 μg/mL CLA, and 0.30 μg/mL RIF
(Table 4). T-cell proliferation was induced by PHA or MAP PPD, which caused relative T-cell
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proliferation levels of 3.60 ± 0.059 and 3.12 ± 0.087, respectively, compared to cells without
these treatments. Relative to the PHA control, it was found that RHB-104, CLA, and RIF
significantly lowered T-cell proliferation in PHA-treated cells (0.75 ± 0.002, 1.09 ± 0.021, and
0.99 ± 0.013, respectively). Likewise, RHB-104, CLA, and RIF also significantly lowered T-cell
proliferation in MAP PPD-treated cells relative to the MAP PPD control (1.09 ± 0.010, 1.76 ±
0.060, and 1.86 ± 0.034, respectively). Furthermore, the reductions in T-cell proliferation caused
by RHB-104 in both PHA- and MAP PPD-treated cell were significantly higher than that caused
by CLA or RIF treatment.
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CHAPTER 4: DISCUSSION
This chapter has been published in part and is reproduced here with permission from the
copyright holder. The article citation is: Qasem, A., Elkamel, E., and Naser, S.A. (2020). AntiMAP Triple Therapy Supports Immunomodulatory Therapeutic Response in Crohn’s Disease
through Downregulation of NF-κB Activation in the Absence of MAP Detection. Biomedicines,
8 (11): 513. doi: 10.3390/biomedicines8110513.
The present study is the first to report the synergistic immunomodulatory and antiinflammatory effects of RHB-104 independent of its bactericidal activity, thus further supporting
its use as a treatment for CD patients. There is an urgent need for improved treatments for CD,
which is characterized by high degrees of inflammation and a possible association with MAP.
RHB-104 drug formulation serves as a promising therapeutic strategy to alleviate disease
symptoms in these patients, even in the absence of MAP detection.
Abnormal accumulation of macrophages, granulocytes, lymphocytes, and platelets is a
well-known characteristic of many inflammatory conditions regardless of their infective or noninfective origins. Consequently, this leads to higher levels of pro-inflammatory cytokine release,
oxidative stress, and local tissue damage. There has been greater emphasis on investigating the
potential anti-inflammatory role of antibiotics in reducing symptoms of these conditions [30]. A
potentially more effective approach to treat inflammatory conditions associated with bacterial
infections is to use a therapeutic compound that has both antimicrobial and anti-inflammatory
mechanisms.
Macrolides are a class of antibiotics that have a broad spectrum of activity against grampositive and some gram-negative bacteria. Specifically, CLA is active against nontuberculous
mycobacteria, including MAP and M. smegmatis [46]. Additionally, CLA attenuates the
production of pro-inflammatory cytokines such as IL-2 and IL-8, which is well-documented both
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in in vitro and in vivo studies [47,48]. Studies have confirmed that CLA exhibits potent antiangiogenic activity through inhibition of vascular endothelial growth factor (VEGF) [49-51].
Macrolides also have unique and favorable pharmacokinetic properties [52]. For instance, the
concentration of CLA in epithelial lung tissue after administration of a certain oral dose is 10fold higher than the plasma concentration level [52]. Moreover, the concentration of macrolides
in inflammatory cells tends to be more than 100-fold higher than that in extracellular fluid, which
enables phagocytic cells to deliver cumulative levels of drugs to sites of infection [53].
The use of rifamycins in the treatment of rheumatoid arthritis (RA) is an interesting
application that also showed an additional anti-inflammatory activity to be associated with this
class of antibiotics [54]. To explain this anti-inflammatory mechanism, a study showed that a
reduction in neutrophil locomotion is caused by rifamycin SV in a concentration-dependent
manner [55]. In addition, rifaximin has been used to suppress the inflammatory response in
gastrointestinal disorders such as inflammatory bowel syndrome (IBS) [56]. Direct intracolonic
administration of rifamycin SV reduced inflammation in dinitrobenzene sulfonic acid-induced
colitis in an animal model [57]. Therefore, combining a macrolide, such as CLA, with a
rifamycin antibiotic, such as RIF, is expected to have promising synergistic immunomodulatory
effects. This could be a useful treatment for several inflammatory conditions, especially those
associated with microbial infection, such as CD.
Our lab previously evaluated the proprietary RHB-104 capsule formulation against a
broad spectrum of microorganisms associated with CD including MAP, Listeria monocytogenes,
and Staphylococcus aureus [46]. The synergistic effect of combining CLA, RIF, and CLO in a
single capsule triple formulation was determined and shown to have a lower MIC compared to
its individual components [46]. This intrigued us to evaluate the anti-inflammatory and
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immunomodulatory effects of RHB-104 and its two major ingredients, CLA and RIF, in vitro to
find out if there is a synergistic anti-inflammatory effect induced by combining these three
antibiotics. The effect of CLO was not tested individually because it makes up only 6.7% of the
RHB-104 formulation.
This study confirmed the bactericidal effects of RHB-104 in MAP-infected macrophages
and investigated the immunomodulatory and anti-inflammatory effects of RHB-104 and its
major components. This was achieved by comparing the effects of RHB-104, CLA, and RIF on
M1/M2 macrophage polarization, NF-κB activation, inflammatory gene expression and protein
levels, anti-cytotoxicity, and T-cell proliferation, all of which have been reported to be increased
in CD patients [42-45]. Since MAP may not be present in all CD cases, LPS was used to induce
an inflammatory response that can be likened to that seen in CD patients as it causes an increase
in NF-κB activation and pro-inflammatory cytokine expression. This also allowed for the
identification of the anti-inflammatory properties of RHB-104 independent of its bactericidal
activity.
The results showed that RHB-104 exhibits synergistic anti-inflammatory effects since it
caused the greatest reduction in the M1/M2 ratio in a dose-dependent manner compared to its
major components. NF-κB activation was also most strongly reduced in response to RHB-104 in
MAP-infected and LPS-treated macrophages compared to its major components, CLA and RIF.
NF-κB is responsible for regulating transcription of the pro-inflammatory cytokines, TNF-α and
IL-6, which are upregulated in CD patients [42,43]. In agreement with this, the results showed
that both TNF-α and IL-6 gene and protein expression were most significantly reduced by RHB104 in a dose-dependent manner compared to its major components in both MAP-infected and
LPS-treated macrophages. The synergistic anti-inflammatory effect caused by RHB-104 may be
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due to the combination of CLA and RIF within the triple antibiotic formulation which have been
shown to independently inhibit NF-κB activation [33,38]. Gene and protein expression of the
anti-inflammatory cytokine, IL-10, was also significantly upregulated only in response to RHB104, but not by treatment with CLA or RIF.
The presence of MAP infection causes systemic inflammation and oxidative stress, which
is characterized by higher levels of glutathione peroxidase (GPx) enzymatic activity [58].
Therefore, tissue damage induced by either DSS or MAP infection was assessed in intestinal
tissue culture, which was most significantly reduced by the presence of RHB-104 treatment as
compared to its major components. Both MAP and DSS were used to confirm that the reduction
in tissue damage caused by RHB-104 was not dependent on anti-MAP activity. Using Caco-2
monolayers, which serve as an effective in vitro model for the intestinal barrier in CD patients,
the results showed reduced LDH activity and increased GSH activity, where LDH is a marker of
tissue damage, and GSH is an antioxidant that is correlated with reduced oxidative stress. As
concluded previously, the synergistic effect of RHB-104 was higher than the effects seen by its
major components. In the aforementioned results, the effect of RHB-104 was stronger in MAPinfected cells compared to LPS- or DSS-treated cells and this is likely because the bactericidal
effects of RHB-104 against MAP contributed to the reduction in inflammation observed.
However, the anti-inflammatory effects of RHB-104 were confirmed to be independent of its
bactericidal activity since inflammation was reduced even in the absence of MAP. The
production of ROS, as indicated by DHE staining, were also reduced in MAP-infected Caco-2
monolayers treated with RHB-104. Finally, the results also showed that RHB-104 caused the
greatest reduction in T-cell proliferation compared to both CLA and RIF following PHA or MAP
PPD stimulation. As CD is characterized by elevated levels of T-cells in the mucosa, the
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modulation of T-cell apoptosis is expected to have therapeutic effects [59]. All these results are
summarized in Figure 11.
The current recommended CD treatment guidelines are based primarily on traditional
immunosuppressive therapeutics such as azathioprine and biological drugs targeting specific proinflammatory cytokines [60]. Nevertheless, up to 40% of CD patients are categorized as nonresponsive to primary treatment, which suggested that these patients should be investigated for
MAP infection and treated with antibiotics accordingly [20,61,62]. Currently, RHB-104 triple
antibiotic combination is the only medicinal product directed against MAP infection, and it is
still under clinical development [37]. The ongoing MAP US global multicenter phase III clinical
trial is using a fixed oral daily dose of RHB-104 to determine its safety and efficacy in treating
moderate to severe active CD over 26 to 52 weeks, considering disease remission as a primary
endpoint [63]. Recent clinical trial reports have demonstrated that RHB-104 causes a
consequential improvement in CD biomarkers of inflammation such as C-reactive protein (CRP)
and Crohn’s disease activity index (CDAI) with or without concomitant anti-TNF-α or
immunosuppressive therapy [41].
Achieving full eradication of mycobacterial infection is considered a relatively
challenging task due to the presence of cell wall deficient forms, slow growth rate, and their
capability of intracellular survival through inhibition of macrophage apoptosis [64,65].
Moreover, MAP can evade host immune detection through several steps of evolved mechanisms,
which complicates its baseline diagnostic results before initiation of antibiotic treatment [66].
However, the presence of mycobacteria in clinical samples does not necessarily mean that it
should be accompanied with clinical pathophysiology as only 4% of latent tuberculosis cases
worldwide develop disease-related symptoms [67]. Therefore, the presence of MAP infection in
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CD patients who underwent antibiotic treatment could explain why these patients continued
testing positive for MAP despite the fact that their CD symptoms were alleviated. In this context,
the data indicate that RHB-104’s immunomodulatory therapeutic properties could be useful for
treating CD patients regardless of MAP infection status.
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APPENDIX A: FIGURES
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Figure 1: Effect of RHB-104 and its major components on MAP viability in infected
macrophages.
*p<0.05.

Figure 2: Effect of RHB-104 and its major components on M1/M2 macrophage polarization in
MAP-infected macrophages.
*p<0.05.
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Figure 3: Effect of RHB-104 and its major components on M1/M2 macrophage polarization in
LPS-treated macrophages.
*p<0.05.

Figure 4: Effect of RHB-104 and its major components on TNF-α, IL-6, and IL-10 expression in
MAP-infected macrophages.
*p<0.05.
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Figure 5: Effect of RHB-104 and its major components on TNF-α, IL-6, and IL-10 expression in
LPS-treated macrophages.
*p<0.05.
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Figure 6: Anti-cytotoxic activity of RHB-104 and its major components in Caco-2 monolayers
infected with MAP.
*p<0.05.
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Figure 7: Anti-cytotoxic activity of RHB-104 and its major components in Caco-2 monolayer
treated with 3% DSS.
*p<0.05.
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Figure 8: Oxidative stress levels demonstrated by DHE fluorescence staining assay following treatment with RHB-104 and its
major components in MAP infected Caco-2 monolayers.
*p value < 0.05 compared to no treatment control. † p value < 0.05 compared to no treatment control and MAP + RIF values.
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Figure 9: Oxidative stress levels demonstrated by DHE fluorescence staining assay following infection with MAP at different
concentrations in Caco-2 monolayers.
*p value < 0.05 compared to no treatment control. † p value < 0.05 compared to all tested MAP concentrations.
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Figure 10: Oxidative stress levels demonstrated by DHE fluorescence staining assay following treatment with RHB-104 at
different concentrations in Caco-2 monolayers.
*p value < 0.05 compared to no treatment control. † p value < 0.05 compared to RHB-104 (0.5 μg/mL).
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Figure 11: Schematic diagram summarizing the immunomodulatory activity of RHB-104.
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APPENDIX B: TABLES
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Table 1: RT-qPCR primer sequences for tested genes.
Forward Primer Sequence
Gene
(5’ → 3’)
5’-CTTTTGCAGACCACAGTCCATG-3’
GAPDH
(22 bases)
5’-GGAGCAACGTTGAGGAAATAAGACT-3’
iNOS
(25 bases)
5’-GGAGGATTCCATGTATTTGTGAGC-3’
CD206
(24 bases)
5’-TCTCCCTCAAGGACTCAGCTTTCTG-3’
TNF-α
(25 bases)
5’-CAGGAGAAGATTCCAAAGATGTAGCC-3’
IL-6
(26 bases)
IL-10

5’-ATGTCTAGTTCAGGCAGTCCCA-3’
(22 bases)
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Reverse Primer Sequence
(5’ → 3’)
5’-TTTTCTAGACGGCAGGTCAGG-3’
(21 bases)
5’-AAGAGCCAGAAGCGCTATCAC-3’
(21 bases)
5’-AAATGAGTGAAGTGAAATCAGTTACCT-3’
(27 bases)
5’-TGAGAGGAAGAGAACCTGCCTGG-3’
(23 bases)
5’-TGCTCTAGAACCCAGCAAAGAC-3’
(22 bases)
5’-GGGCTTGCTCTTGCAAAACC-3’
(20 bases)

Table 2: NF-κB activation scores in macrophages infected with MAP or treated with LPS
following treatment with RHB-104 and its major components.
Antibiotic Concentration
Treatment
NF-κB Activation Score (%)
(µg/mL)
Positive Control
100.0
Negative Control
6.9
0.50
48.4
MAP + RHB-104
1.00
21.5
2.00
13.4
0.32
58.3
MAP + CLA
0.63
49.6
1.26
24.1
0.15
83.8
MAP + RIF
0.30
73.1
0.60
57.5
0.5
67.2
LPS + RHB-104
1.0
37.8
2.0
23.3
0.32
68.2
LPS + CLA
0.63
57.2
1.26
33.6
0.15
89.1
LPS + RIF
0.30
83.4
0.60
68.7
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Table 3: Measurement of TNF-α, IL-6, and IL-10 cytokines in macrophages infected with MAP
or treated with LPS following treatment with RHB-104 and its major components.
Antibiotic
TNF-α ± SD
IL-6 ± SD
IL-10 ± SD
Treatment
Concentration (µg/mL)
(pg/mL)
(pg/mL)
(pg/mL)
MAP Control
191.2 ± 8.6
201.8 ± 11.7
61.9 ± 9.8
LPS Control
217.4 ± 5.1
224.3 ± 9.6
52.2 ± 7.4
No Treatment
75.7 ± 6.5
82.9 ± 5.1
100.4 ± 6.5
0.50
175.3 ± 8.4
182.2 ± 8.1
79.2 ± 2.9
MAP + RHB-104
1.00
123.7 ± 6.7*
139.4 ± 3.2*
88.6 ± 3.5*
2.00
95.8 ± 1.8*
117.5 ± 2.5*
95.1 ± 5.8*
0.32
184.7 ± 3.6
191.5 ± 8.3
68.3 ± 3.1
MAP + CLA
0.63
165.8 ± 5.1
173.6 ± 3.1
75.4 ± 2.7
1.26
146.1 ± 6.2*
153.2 ± 4.6*
80.3 ± 8.7
0.15
187.2 ± 5.3
197.3 ± 7.2
63.6 ± 4.1
MAP + RIF
0.30
179.1 ± 1.9
184.9 ± 5.9
70.2 ± 2.1
0.60
166.4 ± 8.3
172.8 ± 3.9
77.3 ± 3.4
0.5
179.3 ± 2.0
182.6 ± 5.1
76.4 ± 6.3
LPS + RHB-104
1.0
139.7 ± 4.7*
151.1 ± 2.5*
84.3 ± 6.9*
2.0
110.9 ± 4.0*
137.2 ± 2.7*
91.1 ± 5.2*
0.32
185.8 ± 1.6
193.3 ± 4.4
61.2 ± 4.2
LPS + CLA
0.63
162.4 ± 6.2
174.8 ± 3.6
69.7 ± 7.8
1.26
158.2 ± 7.3*
169.7 ± 1.1*
71.9 ± 6.9
0.15
188.3 ± 3.1
206.8 ± 8.0
54.6 ± 2.3
LPS + RIF
0.30
179.7 ± 8.9
192.4 ± 1.3
62.4 ± 7.2
0.60
166.1 ± 5.6
182.1 ± 1.6
67.5 ± 4.9
*p<0.05
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Table 4: T-cell Proliferation Following Treatment with MAP PPD or PHA and RHB-104 and its
Major Components.
T-cell Proliferation
Relative T-cell
Treatment
(OD at 450 nm)
Proliferation
Control (no PHA or MAP PPD)
0.061
1.00 ± 0.003
PHA Control
0.219
3.60 ± 0.059
0.75 ± 0.002*†
PHA + 1.0 µg/mL RHB-104
0.046
PHA + 0.63 µg/mL CLA
0.066
1.09 ± 0.021*
PHA + 0.30 µg/mL RIF
0.060
0.99 ± 0.013*
MAP PPD Control
0.189
3.12 ± 0.087
MAP PPD + 1.0 µg/mL RHB1.09 ± 0.010*†
104
0.066
MAP PPD + 0.63 µg/mL CLA
0.107
1.76 ± 0.060*
MAP PPD + 0.30 µg/mL RIF
0.113
1.86 ± 0.034*
*p value < 0.05 compared to PHA or MAP PPD control; †p value < 0.05 compared to CLA and RIF treatment.
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